A Great Time for a Great Cause: Leveraged Finance Fights Melanoma benefit Set for May 24

melanoma benefitThe Leveraged Finance Fights Melanoma benefit and cocktail party is planned for Wednesday, May 24, at the Summer Garden at Rockefeller Center. Tickets and sponsorship opportunities are available at the Melanoma Research Alliance (MRA) website.

Funds raised at the event will support the Melanoma Research Alliance (MRA), the world’s largest private funder of melanoma research, which was founded in 2007 by Debra and Leon Black under the auspices of the Milken Institute.

Since this event was launched in 2012, the leveraged finance community has come together and generously supported more than $6.8 million of cutting-edge research to make transforming advances in the prevention, diagnosis and staging, and treatment of melanoma.

The event co-hosts are Brendan Dillon from UBS; Lee Grinberg from Elliott Management; George Mueller from KKR; Jeff Rowbottom from PSP Investments; Cade Thompson from KKR; and Trevor Watt from Hellman & Friedman. Attendees include the biggest names in leveraged finance, from all of the top banks, many investment houses, several law firms, select issuers, and some private equity sponsors. As with the prior events, LCD is a proud sponsor.

Kirkland & Ellis is a presenting sponsor. Lead sponsors include Simpson Thatcher, UBS, Leonard Green Partners, Hellman & Friedman, Fitch Ratings, Paul E. Singer Foundation, PSP Investments, Morgan Stanley, Cahill Gordon, Shearman & Sterling, Skadden, Arps, Slate, Meagher & Flom, and Latham & Watkins.

Due to ongoing operational support from its founders, 100% of donations to MRA go directly to support research programs working toward a cure for melanoma, the deadliest type of skin cancer. Since MRA began its work, 11 new treatments have been approved by the FDA.

Funds raised from prior year events have supported 11 MRA research awards at institutions spanning the U.S. These projects focus on targeted and immunotherapy treatments, which boost the immune system to fight off cancer more effectively. The studies address critical research questions to advance the development of new therapies for melanoma patients and inform progress against cancer as a whole.

Tickets are $300. For further information about the event and to purchase tickets, please visit Those seeking information about the event and sponsorship opportunities can contact Rachel Gazzerro of MRA at (202) 336-8947 or [email protected]. — Staff reports

Leave a Reply

Comments are moderated and will not appear until the admin has approved them.